Eli Lilly and Incyte have reported new data from an additional cohort of the Phase III COV-BARRIER clinical trial, demonstrating that baricitinib decreased mortality risk in Covid-19 patients on mechanical ventilation or extracorporeal membrane oxygenation (ECMO). The sub-study data from 101 adults revealed that baricitinib plus standard of care (SoC) led to 46% and 44% reduced mortality risk by day 28 and day 60, respectively, versus placebo plus SoC.
Alnylam Pharmaceuticals is discontinuing the development of ALN-COV, an RNAi therapeutic co-developed with Vir Biotechnology, for the treatment of Covid-19. The decision was announced as part of Alnylam’s second-quarter financial results, with the company noting the discontinuation of development is due to the availability of effective vaccines and other therapies for the disease.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Premas Biotech has entered a licensing agreement with Oravax Medical to develop and commercialise its virus-like-particle (VLP) Covid-19 vaccine technology in India. Premas will receive the rights to develop an injectable version of the VLP technology, which could offer protection against the delta SARS- CoV-2 variant. The company will produce, evaluate and potentially market the injectable VLP vaccine in India, which has recorded about 31 million cases and more than 400,000 deaths so far.
